Overall Net-Zero Target: Tabuk Pharmaceuticals Manufacturing Company commits to achieve net-zero greenhouse gas emissions across the value chain by 2050. Near-Term Targets: Tabuk Pharmaceuticals Manufacturing Company commits to reduce absolute scope 1 and 2 GHG emissions 50.0% by 2030 from a 2021 base year. Tabuk Pharmaceuticals Manufacturing Company also commits to reduce scope 3 GHG emissions from fuel- and energy-related activities, waste generated in operations, business travel, employee commuting, downstream transportation and distribution and franchises 55.0% per unit of pharmaceutical products produced and distributed within the same timeframe. Tabuk Pharmaceuticals Manufacturing Company further commits that 77.94% of its suppliers by emissions covering purchased goods and services, capital goods, upstream transportation and distribution and upstream leased assets, will have science-based targets by 2030. Long-Term Targets: Tabuk Pharmaceuticals Manufacturing Company commits to reduce absolute scope 1 and 2 GHG emissions 95.0% by 2050 from a 2021 base year. Tabuk Pharmaceuticals Manufacturing Company also commits to reduce absolute scope 3 GHG emissions from purchased goods and services, capital goods, upstream transportation and distribution and upstream leased assets 95.0% within the same timeframe. Tabuk Pharmaceuticals Manufacturing Company further commits to reduce scope 3 GHG emissions from fuel- and energy-related activities, waste generated in operations, business travel, employee commuting, downstream transportation and distribution and franchises 97.0% per unit of pharmaceutical products produced and distributed within the same timeframe.